However, we are once again optimistic about the Interventional Cardiology (IC) business, which is likely to have helped the company maintain impressive global growth in the first half of the first quarter, courtesy of an innovative portfolio and robust commercial teams across structural heart and coronary therapies.Additionally, sales of GYN Surgical and certain non COVID-19 Diagnostics products are expected to have been significantly dented in the second quarter of fiscal 2020 due to the deferral of elective procedures and physician office visits.